Holen Sie sich die Stockscreener-App
2.37
0.85%
0.02
Cellectar Biosciences Inc Aktie (CLRB) Neueste Nachrichten
Balyasny Asset Management L.P. Initiates New Position in Cellect - GuruFocus
Cellectar Biosciences (CLRB) Q2 2026 Earnings Call Transcript - AOL.com
Cellectar Biosciences Inc (CLRB) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
CLRB Stock Surged 27% Today – Here’s Why Retail Is Bullish About Cellectar’s Blood Cancer Trial Data - Stocktwits
Cellectar Biosciences, Inc. (CLRB) Discusses Scientific Rationale and Potential of Phospholipid Ether Platform in Targeted Cancer TherapySlideshow (NASDAQ:CLRB) 2026-08-18 - Seeking Alpha
Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlig - GuruFocus
CLRB Q1 2026 Earnings: Narrower-Than-Expected Loss Drives 4.84% Stock RallyEarnings Revision Upgrade - Vinanet
symbol__ Stock Quote Price and Forecast - CNN
Cellectar Biosciences (CLRB): Caligan Partners reports 5.9% ownership stake - Stock Titan
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar’s New Phase 3 WM Trial Puts Iopofosine I 131 on Investors’ Radar - TipRanks
Cellectar Biosciences (CLRB) investor discloses 9.99% stake and warrant holdings - Stock Titan
Cellectar Biosciences (CLRB) investor discloses 9.99% stake via stock and warrants - Stock Titan
Ladenburg Thalmann Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Balyasny Asset Management (CLRB) discloses 9.99% Cellectar stake via stock and warrants - Stock Titan
Cellectar Biosciences, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Cellectar Biosciences (CLRB) ownership: Bleichroeder group reports 9.99% equity stake - Stock Titan
Cellectar Biosciences Releases Q2 2026 Financial Results - AlphaStreet
CLRB Q1 2026 Earnings: Narrower-Than-Expected Loss of $1.30 Per Share as Development Focus Intensifies - vinanet.vn
Earnings call transcript: Cellectar narrows focus on WM as Q2 2026 loss widens - Investing.com
CLRB: Positive clinical results, robust financing, and regulatory momentum drive pipeline advancement - TradingView
Cellectar Biosciences Q2 2026 Earnings Call Transcript - Benzinga
Cellectar Q2 net loss widens 28% to $6.9M, misses EPS estimate - scanx.trade
Cellectar Biosciences reports Q2 2026 net loss $6.9M, cash $34.0M; advances iopofosine Phase 3 - TradingView
CLRB: Strong clinical progress and financing position support upcoming NDA submission in WM - TradingView
Cellectar Biosciences (CLRB) Q2 loss hits $6.9M as cash reaches $34M - Stock Titan
Cellectar Biosciences Q2 net loss widens on higher R&D costs - TradingView
Cellectar Prepares ~100-Patient-Per-Arm Trial, Plans 2027 FDA Filing - Stock Titan
Cellectar Biosciences 6M 2026: Net loss $(12.6M), Diluted EPS $(1.52) — 10-Q Summary - TradingView
Cellectar Biosciences (CLRB) raises $31.7M, flags going concern risk - Stock Titan
Cellectar Biosciences (CLRB) Financials 2026Income Statement and Balance Sheet $CLRB - MarketBeat
Cellectar Biosciences (CLRB) Q1 2026 Earnings: Narrower Loss Beats Consensus by 32.39% as Pre-Revenue Pipeline AdvancesBuyback Announcement Report - vinanet.vn
Cellectar Biosciences Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Empery Asset Management, LP Initiates Position in Cellectar Bios - GuruFocus
Cellectar Biosciences Sets Major Conference Schedule: Pediatric Cancer Data Featured - Stock Titan
Cellectar Biosciences (CLRB) Sets Q3 2024 Earnings Call for Nov 18 - Stock Titan
Cellectar BioSciences (CLRB.US) will release its earnings report before the market opens on August 13. - Moomoo
Empery Asset Management (CLRB) discloses 9.99% beneficial stake via stock and warrants - Stock Titan
CLRB Q1 2026 Earnings: 32.4% EPS Beat Signals Cost Discipline Amid Pipeline ProgressBanking Earnings Report - vinanet.vn
Cellectar Biosciences to Report Second Quarter Financial - GlobeNewswire
Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026 - Yahoo Finance
Cellectar Biosciences (CLRB) Edges Higher Amid Low Volume; Key Support and Resistance in FocusEquity Put Call - dars.gov.et
Cellectar Biosciences (CLRB) Edges Higher as Volume Picks Up at Critical JunctureEMA Signal - vinanet.vn
Cellectar Biosciences Inc (CLRB) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cellectar Biosciences Inc (CLRB) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
CLRB|Cellectar Biosciences Inc|Price:2.410|Chg%:-0.060 - TradingKey
Cellectar Biosciences Inc (CLRB) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TradingKey - TradingKey
Cellectar Biosciences Inc (CLRB) Balance Sheet - TradingKey
Cellectar Biosciences Inc (CLRB) Cash Flow - TradingKey
Cellectar Biosciences (CLRB) Q1 2026 earnings summary - Quartr
Cellectar Biosciences (CLRB) Proxy filing Summary - Quartr
Cellectar Biosciences (CLRB) Q4 2025 earnings summary - Quartr
Cellectar Biosciences (CLRB) Registration filing Summary - Quartr
Cellectar BioSciences publishes corporate presentation on phospholipid drug conjugate radiotherapy pipeline, led by iopofosine I-131 in Waldenstrom macroglobulinemia - Bitget
Cellectar Publishes Phase 1 Iopofosine Data - t.co
Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers - Sahm
Cellectar publishes phase 1 data on multiple myeloma treatment By Investing.com - Investing.com South Africa
Cellectar Biosciences (CLRB) Announces Positive Phase 1 Study Re - GuruFocus
Cellectar publishes phase 1 data on multiple myeloma treatment - Investing.com
Cellectar Biosciences Announces Publication of Phase 1 Data for Iopofosine I 131 in Relapsed/Refractory Multiple Myeloma - Quiver Quantitative
Cellectar Myeloma Data: 84.6% of 26 Evaluable Patients Stable or Better - Stock Titan
Brookline Capital Initiates Cellectar BioSciences(CLRB.US) With Buy Rating, Announces Target Price $15 - Moomoo
Cellectar Biosciences (CLRB) Slides 5.5% as Selling Pressure Intensifies Near SupportSector Sentiment - vinanet.vn
Cellectar Biosciences (CLRB) Stock Fair Value Moves Lower As Analysts Weigh Execution Risk - Yahoo Finance
0.86%
0.31%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):